Diagenode

MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199


Benito JM et al.

Targeted therapies designed to exploit specific molecular pathways in aggressive cancers are an exciting area of current research. Mixed Lineage Leukemia (MLL) mutations such as the t(4;11) translocation cause aggressive leukemias that are refractory to conventional treatment. The t(4;11) translocation produces an MLL/AF4 fusion protein that activates key target genes through both epigenetic and transcriptional elongation mechanisms. In this study, we show that t(4;11) patient cells express high levels of BCL-2 and are highly sensitive to treatment with the BCL-2-specific BH3 mimetic ABT-199. We demonstrate that MLL/AF4 specifically upregulates the BCL-2 gene but not other BCL-2 family members via DOT1L-mediated H3K79me2/3. We use this information to show that a t(4;11) cell line is sensitive to a combination of ABT-199 and DOT1L inhibitors. In addition, ABT-199 synergizes with standard induction-type therapy in a xenotransplant model, advocating for the introduction of ABT-199 into therapeutic regimens for MLL-rearranged leukemias.

Tags
Antibody

Share this article

Published
December, 2015

Source

Related product

  • Histone-Deacetylase-polyclonal-antibody-diagenode
    C15410196
    H3K27ac polyclonal antibody - Premium
  • Histone-Deacetylase-polyclonal-antibody-diagenode
    C15410194
    H3K4me1 polyclonal antibody - Premium
  • Histone-Deacetylase-polyclonal-antibody-diagenode
    C15410003-50
    H3K4me3 polyclonal antibody - Premium
  • Histone-Deacetylase-polyclonal-antibody-diagenode
    C15410068
    H3K79me3 polyclonal antibody - Classic

Events

 See all events

Twitter feed

News

 See all news